Honeycomb lung is the term doctors use for end-stage pulmonary fibrosis, a condition in which healthy lung tissue has been replaced by clusters of thick-walled cysts that, on a scan or under a microscope, resemble a honeycomb. It is not a disease in itself but rather the final common endpoint of several different lung diseases, most often idiopathic pulmonary fibrosis (IPF). Because honeycombing signals irreversible scarring, its presence on a CT scan changes both the diagnosis and the conversation about what comes next.
What Honeycomb Lung Actually Looks Like
The name is descriptive. On a high-resolution CT scan (HRCT), honeycomb lung appears as tightly grouped cystic air spaces, usually between 3 and 10 millimeters across, with clearly defined shared walls.1European Journal of Radiology. Honeycombing on CT; its definition, pathologic correlation, and future direction of its diagnosis These cysts tend to cluster along the outer edges of the lungs, particularly at the bases, giving the tissue its characteristic appearance. The term was originally broader, used to describe any lung condition that produced multiple cysts visible to the naked eye, but over time it narrowed. Today it refers specifically to irreversible fibrotic remodeling of the lung.2PubMed. Honeycomb lung: history and current concepts
What makes honeycombing particularly important on imaging is that it can look similar to other conditions. Emphysema with bullae, cystic bronchiectasis, and even certain rare cystic lung diseases can mimic the honeycomb pattern, which means radiologists have to be precise about what they are calling honeycombing and what they are not. Misidentifying another process as true honeycombing can lead to a wrong diagnosis and inappropriate treatment.
Conditions That Cause Honeycombing
Several diseases can scar the lungs badly enough to produce a honeycomb pattern. The most common is idiopathic pulmonary fibrosis, where “idiopathic” simply means the cause is unknown. IPF follows a pattern called usual interstitial pneumonia (UIP), and honeycombing is one of the hallmark findings that radiologists look for when diagnosing it.3European Respiratory Review. Imaging: how to recognise idiopathic pulmonary fibrosis But IPF is far from the only route to honeycomb lung.
Connective tissue diseases, particularly systemic sclerosis and the inflammatory myopathies, can trigger interstitial lung disease that progresses to honeycombing. In these autoimmune conditions, the immune system’s attack on the body’s own tissues extends to the lungs. Honeycombing in this context tends to indicate a UIP-like pathological pattern and suggests more advanced fibrosis compared to other imaging patterns like ground-glass opacities.4PubMed Central. Diagnostic significance of HRCT imaging features in idiopathic inflammatory myopathy-associated interstitial lung disease
Environmental and occupational exposures are another major category. Asbestos exposure, for example, can produce fibrosis concentrated at the lung bases, and honeycombing in those lower zones is a common finding in asbestosis. Chronic hypersensitivity pneumonitis, caused by repeated inhalation of organic dusts like mold, bird proteins, or certain chemicals, can also progress to honeycombing, though it tends to appear in the upper parts of the lungs rather than the bases.5PubMed Central. High-resolution computed tomography features of asbestosis versus fibrotic hypersensitivity pneumonitis: an observational study That difference in location is one of the clues radiologists use to tell these conditions apart.
Certain medications can also damage the lungs to the point of fibrosis. Chemotherapy agents, some antibiotics, antiarrhythmic drugs like amiodarone, and immunosuppressive medications have all been associated with drug-induced interstitial lung disease that can, in some cases, produce honeycombing.6PubMed Central. Drug induced interstitial lung disease This category is worth knowing about because it is one of the few where the triggering cause can be identified and stopped, which is not always possible with other forms of pulmonary fibrosis.
How Where the Honeycombing Sits Helps Narrow the Cause
The distribution of honeycombing across the lungs provides surprisingly useful diagnostic information. A definite UIP pattern on HRCT, which points toward IPF, requires honeycombing that is predominantly in the lower lobes and along the outer edges of the lung. The full diagnostic criteria also call for a reticular (net-like) pattern, and the absence of features that would point away from UIP, such as extensive ground-glass opacity or a mosaic pattern suggesting airway disease.3European Respiratory Review. Imaging: how to recognise idiopathic pulmonary fibrosis
When honeycombing shows up in the upper lobes instead, clinicians start thinking about chronic hypersensitivity pneumonitis or, less commonly, sarcoidosis. Asbestosis tends to produce basal honeycombing similar to IPF, but additional findings like pleural plaques or diffuse pleural thickening help distinguish it.5PubMed Central. High-resolution computed tomography features of asbestosis versus fibrotic hypersensitivity pneumonitis: an observational study In practice, radiologists and pulmonologists piece together the location of the honeycombing, the patient’s history of exposures and medications, bloodwork for autoimmune markers, and sometimes a lung biopsy to arrive at the underlying diagnosis.
Symptoms That Accompany Honeycomb Lung
Because honeycomb lung represents advanced scarring, the symptoms are those of significant lung impairment. The most common are progressive breathlessness, particularly with exertion, and a persistent dry cough. These symptoms develop gradually, often over months or years, and tend to worsen steadily. Fatigue is another frequent complaint, driven partly by the effort of breathing with stiffened, scarred lungs and partly by the lower oxygen levels that result from impaired gas exchange.
One physical finding that clinicians associate strongly with fibrotic lung disease is a distinctive crackling sound heard through a stethoscope, often called Velcro crackles because they sound like peeling apart Velcro strips. Research has shown that the presence of these crackles correlates independently with the extent of honeycombing and other fibrotic features on CT imaging.7PubMed Central. “Velcro-type” crackles predict specific radiologic features of fibrotic interstitial lung disease For a primary care doctor hearing these crackles during a routine exam, especially in someone with unexplained cough and shortness of breath, they are a strong prompt to order a chest CT. Finger clubbing, where the tips of the fingers become rounded and bulbous, is another physical sign that can show up in advanced pulmonary fibrosis.
Anxiety and depression are common among people living with advanced interstitial lung disease, and they are often underrecognized. The sensation of struggling to breathe is inherently distressing, and the progressive nature of the disease adds psychological weight.
How Doctors Diagnose and Measure Honeycombing
High-resolution CT is the cornerstone of diagnosis. A standard chest X-ray can suggest fibrosis, but HRCT provides the detail needed to identify honeycombing, assess its distribution, and distinguish it from conditions that mimic it. The scan shows the clustered cysts, their wall thickness, and whether they follow the subpleural, basal-predominant pattern typical of UIP or a different distribution that points elsewhere.
Pulmonary function tests complement the imaging. In fibrotic lung disease, the lungs become stiff and lose volume, so forced vital capacity (the total amount of air you can blow out) drops. The lung’s ability to transfer oxygen into the bloodstream, measured by the diffusing capacity for carbon monoxide (DLCO), also falls. Quantitative CT analysis has confirmed that as honeycombing and other fibrotic changes increase on imaging, these functional measurements decline in parallel.8PubMed Central. Correlations between quantitative computed tomography metrics with serum fibrosis biomarkers, pulmonary function, and mortality risk in patients with idiopathic pulmonary fibrosis: a prospective cohort study
In cases where the imaging and clinical picture are not straightforward, a surgical lung biopsy may be needed. This is more invasive and carries its own risks, so it is generally reserved for situations where the CT pattern is ambiguous or where confirming the specific type of interstitial lung disease would change the treatment approach. Blood tests for autoimmune antibodies, a careful occupational and environmental exposure history, and sometimes bronchoalveolar lavage (washing a segment of the lung with fluid and analyzing the cells) round out the diagnostic workup.
What Honeycombing Means for Prognosis
The presence and extent of honeycombing carry real prognostic weight. In one study of patients with combined pulmonary fibrosis and emphysema, those with less than 5% honeycombing on CT had a five-year survival rate of about 79%, while those with 26 to 50% honeycombing had a five-year survival of only 32%. Each increase in the extent of honeycombing nearly doubled the risk of death.9PubMed Central. Visually stratified CT honeycombing as a survival predictor in combined pulmonary fibrosis and emphysema DLCO was independently linked to survival as well, reinforcing that both the structural damage visible on imaging and the functional impairment it causes matter for predicting outcomes.
Advanced honeycomb lung also raises the risk of serious complications. Pulmonary hypertension, where blood pressure in the arteries of the lungs rises abnormally, is common in advanced IPF and is itself tied to worse survival. One study found that pulmonary hypertension at baseline more than doubled the risk of acute exacerbations, which are sudden, severe flare-ups of disease that are often fatal.10PubMed. Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis An interesting finding from that same research was that blood vessel formation was actually reduced in areas of honeycombing compared to areas of active fibrosis, suggesting that the honeycomb cysts represent tissue that has essentially been abandoned by the body’s vascular supply.
Treatment Options and Their Limits
No medication reverses honeycombing once it has formed. The scarring is permanent. Treatment instead focuses on slowing the progression of the underlying fibrotic disease and managing symptoms. For IPF, the two approved antifibrotic drugs, pirfenidone and nintedanib, can slow the decline in lung function, reduce symptoms, and improve quality of life, but they do not cure the disease.11PubMed Central. Idiopathic pulmonary fibrosis: Current and future treatment Lung transplantation is the only intervention that has been shown to extend life expectancy in IPF patients, though it comes with its own significant risks and the lifelong need for immunosuppressive medication.
For patients with fibrotic lung disease who are being considered for transplant, current best practice is to continue antifibrotic therapy right up until the time of surgery. Research has shown that doing so is safe and does not increase complications around the transplant itself.12European Respiratory Review. Antifibrotic drugs in lung transplantation and chronic lung allograft dysfunction: a review Supplemental oxygen, pulmonary rehabilitation (structured exercise programs tailored for lung disease), and treatment for associated conditions like gastroesophageal reflux are all part of the broader management plan.
When the underlying cause is something identifiable, addressing it can sometimes halt further progression. Removing a patient from an offending occupational exposure, or stopping a drug that is causing lung toxicity, may prevent additional damage. One case report described a patient who developed interstitial lung disease from a chemotherapy drug called tegafur-uracil; once the drug was identified as the culprit through specific testing and stopped, the inflammation could be managed.13PubMed Central. A Case of Tegafur-Uracil-Induced Interstitial Lung Disease Presenting as Hypersensitivity Pneumonitis Even in those cases, any honeycombing that has already developed will not reverse, but further scarring can be prevented.
End-of-Life Care Gaps
One of the less discussed aspects of honeycomb lung and advanced interstitial lung disease is how poorly the end-of-life experience is often managed. Research has found that most patients with interstitial lung disease die in hospitals rather than in palliative or hospice settings, and involvement with palliative care services tends to be low. Death is more likely to come unexpectedly for people with interstitial lung disease compared to those with other conditions, and the dominant symptoms in the final phase, severe breathlessness, persistent cough, fatigue, anxiety, and depression, are often inadequately addressed. Patients with interstitial lung disease were far less likely to die in a palliative setting compared to patients with other terminal illnesses.
This matters because early conversations about goals of care, advance directives, and symptom management can substantially improve the experience for both patients and families. The progressive and unpredictable nature of fibrotic lung disease makes advance care planning particularly valuable, yet it happens less than it should. If you or someone you know has been diagnosed with advanced pulmonary fibrosis, asking the treatment team about palliative care early in the course is reasonable and does not mean giving up on active treatment. Palliative care and disease-directed treatment can run in parallel.
Artificial Intelligence in Detecting and Measuring Honeycombing
A growing area of research involves using artificial intelligence to analyze CT scans for honeycombing and other fibrotic patterns. The appeal is consistency: two radiologists can look at the same scan and disagree about whether a finding represents true honeycombing or something else, and visual scoring of honeycombing extent is inherently subjective. AI tools trained to recognize specific texture patterns can quantify honeycombing as a percentage of lung volume, potentially reducing that variability.
One study using AI-based texture analysis in patients with bronchiectasis found that honeycombing increased from about 3% of lung volume in mild cases to roughly 12% in severe cases, tracking closely with disease severity.14PubMed Central. Artificial Intelligence Unveils the Unseen: Mapping Novel Lung Patterns in Bronchiectasis via Texture Analysis In systemic sclerosis, researchers have demonstrated that AI software can reliably analyze even non-standard CT scans and produce consistent measurements of honeycombing, reticular patterns, and ground-glass opacities.15PubMed Central. Non-contiguous computed tomography lung scans can be manipulated to permit artificial intelligence analyses for interstitial lung disease in systemic sclerosis These tools are not yet replacing radiologists, but they are increasingly being explored as aids for tracking disease progression over time and for standardizing the kind of visual scoring that currently varies from reader to reader.
Quantitative CT analysis, whether performed by AI or by specialized software under human supervision, is also being paired with blood-based biomarkers of fibrosis. The goal is to build a more complete picture of where a patient stands, combining what the scan shows structurally with what the bloodwork reveals about ongoing fibrotic activity, and to do it in a way that is reproducible enough to use in clinical trials testing new therapies.8PubMed Central. Correlations between quantitative computed tomography metrics with serum fibrosis biomarkers, pulmonary function, and mortality risk in patients with idiopathic pulmonary fibrosis: a prospective cohort study For patients, the practical upshot may eventually be earlier detection of worsening and more precise timing of treatment adjustments.